Latest Breaking News On - Torre fornell - Page 1 : comparemela.com

Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook

2022 objectives successfully met, notably in the development of the two drug candidates: AEF0117: phase 2b study in the United States progressing as expected AEF0217: the compound's

Aelis Farma Reports Its 2022 Annual Financial Results and Confirms Its 2023 Outlook

Aelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day

Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders

AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which